XERESE (acyclovir and hydrocortisone) by Bausch + Lomb is dna polymerase inhibitors [moa]. Approved for herpes simplex virus nucleoside analog dna polymerase inhibitor [epc]. First approved in 2009.
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
XERESE is a fixed-dose topical cream combining acyclovir (a nucleoside analog DNA polymerase inhibitor) and hydrocortisone for the treatment of herpes simplex virus infections. The acyclovir component inhibits viral DNA replication, while hydrocortisone reduces inflammation and associated symptoms. This combination targets the localized treatment of HSV lesions on the face and lips.
Declining commercial activity with minimal Part D uptake signals a mature, low-volume product with limited team expansion opportunity.
DNA Polymerase Inhibitors
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on XERESE offers limited career growth opportunity; the product is in decline with minimal job openings and low commercial momentum. Professionals joining this team should expect focus on cost management, market maintenance, and transition planning rather than expansion.
Worked on XERESE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo